Skip to main content
Loading

CellVax Therapeutics Inc.

October 18, 2023
Franciscan B
Gene/Cell Therapy
Company Description: CellVax Therapeutics is a privately-held clinical-stage company active in research, development, and innovation on human immunodiagnostic and autologous anticancer vaccines, developing proprietary cell-based cancer immunotherapy. The company's lead product, FK-PC101, is an ant-cancer vaccine for prostate cancer patients with a higher risk of recurrence after prostatectomy. FK-PC101 is based on the proprietary novel technology using the patient's own cancer cells to create specific tumor-presenting cells (TPC).
Speakers
Fernando Kreutz, Chief Executive Officer - CellVax Therapeutics